deltatrials
Completed PHASE1/PHASE2 NCT00002832

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation

Sponsor: M.D. Anderson Cancer Center

Conditions Leukemia Myelodysplastic Syndromes
Interventions Allogeneic Bone Marrow Transplantation Cyclosporine Decitabine Filgrastim Peripheral Blood Stem Cell Transplantation
Updated 5 times since 2017 Last updated: Jul 27, 2012 Started: Aug 31, 1995 Primary completion: Mar 31, 2002 Completion: Mar 31, 2002

This PHASE1/PHASE2 trial investigates Leukemia and Myelodysplastic Syndromes and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 5 recorded versions since 1995 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Aug 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States